**Name of Journal:** ***World Journal of*** ***Gastroenterology***

**Manuscript NO: 39416**

**Manuscript Type: REVIEW**

**Long non-coding RNAs involved in metastasis of gastric cancer**

Lin MT *et al*.Sum-up of GC metastatic related lncRNAs

Meng-Ting Lin, Hao-Jun Song, Xiao-Yun Ding

**Meng-Ting Lin,** Medical School of Ningbo University, Ningbo 315000, Zhejiang Province, China

**Hao-Jun Song, Xiao-Yun Ding,** Gastroenterology Department, Ningbo First Hospital, Ningbo 315000, Zhejiang Province, China

**ORCID number:** Meng-Ting Lin (0000-0002-3632-3325); Hao-Jun Song (0000-0001-5796-0967); Xiao-Yun Ding (0000-0002-3731-3508).

**Author contributions:** Lin MT wrote the paper; Song HJ and Ding XY revised this manuscript; all of the authors gave their approval of the final version.

**Supported by** the Natural Science Foundation of Ningbo, No. 2014A610226 and No.2016A610158; the Scientific Benefit for People Project of Ningbo, No. 2014C51001.

**Conflict-of-interest statement:** Authors declare no conflict of interests for this article.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to: Xiao-Yun Ding, MD, PhD, Chief Doctor, Occupational Physician,** Gastroenterology Department, Ningbo First Hospital, No. 59 Liu Ting Street, Haishu District, Ningbo 315000, Zhejiang Province, China. dyyyding@126.com

**Telephone:** +86-574-87085588

**Fax:** +86-574-87291583

**Received:** April 25, 2018

**Peer-review started:** April 25, 2018

**First decision:** May 16, 2018

**Revised:** May 22, 2018

**Accepted:** June 27, 2018

**Article in press:**

**Published online:**

**Abstract**

Gastric cancer (GC) is one of the most frequent malignant diseases. The molecular mechanisms of metastasis remain unclear. Recent, studies have shown that long non-coding RNAs (lncRNAs) play critical roles in metastasis; therefore, deeper understanding of this mechanism could provide utilized diagnosis tools and therapeutic targets of metastasis in GC. This review focuses on dysregulated lncRNAs in GC metastases. Due to the identification of multiple diverse mechanisms involved in GC metastasis, we classified them into seven categories, including lncRNAs related to epithelial-mesenchymal transition (EMT), regulation of degradation of extracellular matrix (ECM), angiopoiesis and vasculogenic mimicry and immunologic escape. As the TNM stage is pivotal for evaluating the severity and prognosis of GC patients, we summarize the lncRNAs relevant to lymphatic metastasis, distant metastasis and TNM classification. This review summarizes in category the metastatic related lncRNAs, which may help to understand the mechanism map of mentioned lncRNAs, and may provide potential markers for prognostic prediction and monitoring relapse of GC. These mechanisms could be possible targets to intervene metastasis GC.

**Key words**: Long noncoding RNAs; Stomach neoplasms; Metastasis

**© The Author(s) 2018.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** This review summarizes the long noncoding RNAs (lncRNAs) that influence metastasis of gastric cancer. We classified lncRNAs according to their molecular mechanism, which included epithelial-mesenchymal transition, epigenetic regulation, degradation of the extracellular matrix, angiopoiesis, vasculogenic mimicry and immunologic escape. Finally, we summarized the lncRNAs that have stable expression in serum and describe their clinical value. A table lists the clinical correlation of the lncRNAs in details.

Lin MT, Song HJ, Ding XY. Long non-coding RNAs involved in metastasis of gastric cancer. *World J Gastroenterol* 2018; In press

**INTRODUCTION**

Gastric cancer (GC) is a major public health problem across the life span of human beings and is one of the top two leading causes of cancer-related death worldwide. Eastern Asia has the highest incidence rates of GC, which is particularly prevalent in China[1]. According to statistical analysis, lung cancer is the only cancer with higher rates of incidence and mortality compared to stomach neoplasms[2]. Approximately 28000 cases of gastric neoplasms are expected to be diagnosed in 2017, and 10960 of them are expected to result in death[3]. Patients are usually diagnosed with GC after metastasis has occurred or in an advanced stage due to limitations in early noninvasive detection techniques. Even when diagnosed at an early stage and endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) are successfully performed, the local recurrence rate is still high, ranging from 2.8%-12.5%[4,5]. The post-operative monitoring tools including endoscopic monitoring, CT, MRI, PET, serological monitoring (CA19-9,CA153,CA125,CA724), though the sensitivity did not match our expectation yet. Recent, circulating tumor DNA (ctDNA) are being considered as GC relapse predicting markers[6,7]. Because of the unsatisfactory prognosis in advanced stage GC patients who have undergone surgery, chemotherapy or radiotherapy, measures should be taken to intensively monitor GC patients[8]. In recent years, significant advances have been made in understanding the molecular mechanisms involved in GC metastasis, however, the overall view of the mechanism map is limited and ambiguous[9,10]. Therefore, clarification of the pathogenesis and corresponding molecular alterations in GC is imperative in seeking diagnostic biomarkers and therapeutic targets.

Noncoding RNAs (ncRNAs) longer than 200 nucleotides are defined as long noncoding RNAs (lncRNAs). ncRNAs are emerging elements that are recognized to play critical roles in cancer development and progression. LncRNAs do not perform transcriptional tasks, but they can affect gene expression at the transcriptional or post-transcriptional levels[11-13].

Increasingly, lncRNAs have been found to participate in GC metastasis. lncRNAs function by impacting embryogenesis, epigenetic regulation, imprinting, angiopoiesis and vasculogenic mimicry[14-18]. This article reviews the lncRNAs that regulate certain critical steps of GC metastasis, with particular emphasis on epithelial-mesenchymal transition (EMT), vascularization and vasculogenic mimicry.

**LNCRNAS EFFECT EMT**

EMT is a vital process involved in embryonic development and cancer metastasis[19]. EMT is the process by which epithelial cells gain increasing migratory potential and mesenchymal characteristics[20]. And it has been shown to play an important role in GC metastasis. There are many lncRNAs that facilitate GC metastasis *via* EMT (Figure 1).

Chen *et al*[14] showed that metastasis associated lung adenocarcinoma1 (MALAT1) is downregulated in GC cells, and that E-cadherin expression is increased while vimentin expression is decreased at both the mRNA and protein levels. Li *et al*[21] detected UPF1, a key part of the nonsense-mediated mRNA decay (NMD) pathway, which alters mRNA transcription, and showed that it negatively correlated with MALAT1 expression. Subsequent experiments showed that increased UPF1 expression inhibited migration, invasion and EMT of GC cells. Increased MALAT1 expression decreased the influence of UPF1 in GC cells, including UPF1’s ability to inhibit cell proliferation, EMT and facilitate apoptosis. Taken together, Li *et al*[22] postulated that UPF1 directly binds MALAT1 to downregulate MALAT1 (UPF1/MALAT1), thus, inhibiting GC progression. Lee *et al*[23] further confirmed that MALAT1 through regulating mesenchymal maker Snail, N-cadherin and ZEB1 to influence EMT. Another classic lncRNA, HOX transcript antisense intergenic RNA (HOTAIR) , has been shown to be elevated in GC cells and promote gastric tumor metastasis *via* enhancement of EMT. E-cadherin expression was higher in cells with HOTAIR knockdown compared to cells with HOTAIR overexpression, while expression of N-cadherin and vimentin were decreased. The detailed mechanism is believed to involve HOTAIR recruitment and binding of PRC2 to epigenetically silence miR34a, which activates the HGF/c-Met /Snail pathway, thus facilitating EMT in tumor cells[24]. FRLnc1 is also upregulated in GC cell lines. *In vitro* functional analysis and a pulmonary metastasis model demonstrated that FRLnc1 enhanced the migration capacity of GC cells. Hui *et al*[25] discovered that FRLnc1 functions as an EMT promoter to affect the migration of GC cells by upregulating the downstream elements TGFβ-1 and Twist. LncRNA activated by TGF-β (lncRNA-ATB), also known as lncRNA-AL (ENST00000493038), was overexpressed in TGF-β treated cancer cells, with the cells exhibiting a spindle-like morphology. lncRNA-ATB induced ZEB1 expression and inhibited miR-200s in tumor cells to effect EMT in stomach neoplasm cells. Saito *et al* uncovered a positive correlation between TGF-β, ZEB1 and lncRNA-ATB, while miR-200c inversely correlated with lncRNA ATB expression. Saito *et al*[26]demonstrated that lncRNA-ATB participate in the EMT process in GC *via* the TGF-β/miR-200/ZEB axis. It has been reported that the lncRNA X-inactive specific transcript (lncRNA XIST) regulates activation of tumor cell migration and initiates EMT *via* upregulation of vimentin and fibronectin and downregulation of E-cadherin and α-catenin in stomach cancer cells. lncRNA XIST negatively correlates with miR-101 and decreased lncRNA XIST expression led to downregulation of EZH2 at both the mRNA and protein levels and was reversed with an miR-101 inhibitor. Thus, lncRNA XIST functions by sponging miR-101 and regulating EZH2 in GC cells[27]. The lncRNA small nucleolar RNA host gene 6 (SNHG6) is overexpressed in GC cell lines and facilitates EMT as a competing endogenous (ce) RNA *via* sponging miR-101-3p, which leads to an increase in ZEB1, thus boosting tumor cell migration at the post-transcriptional level[28]. The lncRNA zinc finger antisense1 (ZFAS1) expression level is elevated in GC tissues, serum and exosomes and ZFAS1 also activates ZEB1 to effect EMT. Lei *et al*[29] showed that ZFAS1 promotes the transformation from mesenchymal-epithelial transition (MET) to EMT by increasing the expression of N-cadherin, Slug, Snail, Twist and ZEB1 and decreasing the expression of E-cadherin. Exosomes that originate from GC cells might promote the GC metastasis by producing ZFAS1. lncRNA urothelial carcinoma associated 1 (UCA1) is induced by TGFβ-1 and expedites EMT. As UCA1 knockdown partly mitigates the impact of TGFβ-1 on EMT, the specific role of TGFβ-1 in accelerating EMT requires further investigation[30]. Silencing UCA1 inhibits resistance to adriamycin in GC, which suggests that UCA1 may be a novel therapeutic target[31].LincRNA00978 is reportedly elevated in GC tissues and plasma, it could induce EMT by activating the TGFβ/SMAD2/MMP9 pathway. Another potential pathway is composed of downregulated LincRNA00978, leading to decreased Twist1 and Slug, followed by a decrease in downstream molecules, such as N-cadherin and vimentin and an increase in E-cadherin[32]. Yes-associated protein1 (YAP1) also promote EMT by upregulating vimentin and β-catenin, downregulating E-cadherin[33]. lncRNAs highly upregulated in liver cancer(HULC) and Linc00152 also increase tumor cell’s migration through acceleration of EMT in GC[34,35].

The lncRNAs mentioned above function by promoting EMT in GC cells, but there are also numerous lncRNAs that function by repressing EMT progression.

Linc00261, which is repressed in GC cells, suppresses E-cadherin and promotes N-cadherin, FN1 and vimentin expression; reverses EMT in gastric tumor cells; and increases the malignant phenotype[36]. Yu *et al*[37] deduced that Linc00261 reverses EMT by binding Slug. As mass experiments indicated that GSK3β affects the ubiquitin-proteasome pathway to degrade Slug in breast cancer cells[38,39], additional experiments demonstrated that Linc00261 attenuates the stability of Slug proteins through strengthening the interaction between GSK3β and Slug. Linc00675, also found to be significantly downregulated in GC tissues, suppresses the migration of GC both *in vitro* and *in vivo* (pulmonary and hepatic metastases). Mechanistic studies showed that Linc00675 directly interacts with vimentin, resulting in increased phosphorylation of vimentin on Ser83 rather than on Ser39, thereby causing the degradation of vimentin filaments[40,41]. Since vimentin is considered to be a master regulator of EMT, Linc00675 was deduced to be a tumor repressor that inhibits metastasis *via* reversing EMT[42]. lncRNA SPRY4 intronic transcript 1 (lncRNA SPRY4-IT1), prevents cancer cell migration partly through its role in the regulation of EMT. Xie *et al*[43] found that SPRY4-IT1 increases the expression of E-cadherin and decreases the expression of vimentin, resulting in EMT inhibition. After observing significantly decreased lncRNA: chr2:118381039-118383698 levels in GC tissue, Han *et al*[44] named this lncRNA LEIGC and assessed its role in regulating tumor cell migration. In monolayer cultures, cells with downregulated LEIGC showed a dramatic change in morphology and transitioned from a cobblestone-like-shape to a spindle-like fibroblastic status, whereas LEIGC-overexpressing cells maintained a cobblestone-like morphology. In addition, mRNA and protein levels illustrated that LEIGC could reverse EMT by lowering the expression of vimentin, Snail, Slug, Zeb, and Twist and increasing the expression of E-cadherin. Furthermore, LEIGC overexpression enhances the GC cells sensitivity of 5-fluorouracil, and this characteristic enable LEIGC to be a potential therapeutic target.

**LNCRNAS AFFECT EPIGENETIC REGULATION IN GC**

Epigenetic processes include the recruitment of histone-modifying enzymes and DNA methyltransferases and chromatin remodeling. It has been reported that lncRNAs interact with DNA to control gene expression[45]. Given that promoter CpG island hypermethylation, an abnormal DNA modification, is involved in pivotal cellular pathways and is characteristically a hallmark of cancer cells[46], several lncRNAs have been found to play roles in controlling the DNA modification system in GC cells.

Sun *et al*[15] evaluated the genome-wide expression profile of lncRNAs and discovered BC041951, designating it as gastric cancer-associated lncRNA 1 (GClnc1). Since mice injected with GClnc1silence cells had an increased overall survival time and more metastatic lung nodules than control mice, GClnc1 was determined to enhance the metastatic capability of tumor cells. The mechanism behind GClnc1’s carcinogenesis stems from its ability to function as a molecular scaffold for the WDR5/KAT2A complex, which leads to trimethylation of H3K4 and acetylation of H3K9 in the transcription promoter region of superoxide dismutase mitochondrial (SOD), which upregulates the transcription of superoxide dismutase 2 mitochondrial (SOD2). LOC100130476, which is dysregulated in gastric cardia adenocarcinoma, is considered to be a tumor suppressor due to the tumor-specific hypermethylation of region 1 near the transcription start site. Methylation of region 1 in peripheral white blood cells had a similar effect and may play key roles in gene silencing. Advanced gastric carcinoma patients with low hypermethylation of region 1 preferentially developed metastases, leading to poor prognosis[47]. Xie *et al*[43] also determined that lncRNA SPRY4-IT1 is downregulated in gastric tumor cells and tissues. Furthermore, Sun *et al*[48] identified a canonical CpG island in the SPRY4-IT1 loci promoter region. DNMT1 inhibits expression of SPRY4-IT1 in GC cells by altering the DNA methylation level. After treatment with 3.7- and 2.8-fold 5-aza-CdR, the expression of SPRY4-IT1 was significantly higher than in controls; therefore, SPRY4-IT1 could be a potential therapeutic target[43].

**LNCRNAS INVOLVED IN REGULATION OF DEGRADATION OF THE EXTRACELLULAR MATRIX**

Tumor cells are exposed to a multitude of abnormal situations due to changes in the ECM that significantly impact cancer cell behavior. Dysregulated ECM cross-linking and repressed stiffness jointly contribute to cancer metastasis and progression[49,50]. Metalloproteases (MMPs) typically participate in adjusting the ECM and vascularization[51].

The lncRNA UCA1 facilitates GC cell migration both *in vitro* and *in vivo* *via* the UCA1/GRK2/ERK/MMP9 axis. Meanwhile, the lncRNA UCA1 increases the degradation of GRK2 *via* Cbl-c-mediated ubiquitination following the activation of the ERK-MMP9 pathway, which may involve in vascularization[52]. Xu *et al*[16] found that FENDRR negatively correlated with FN1 mRNA and that the induction of FENDRR strongly inhibits the activity of MMP2/MMP9, which corroborates FENDRR’s role in preventing GC cell metastasis. Then, Park *et al*[53] determined that overexpression of BM742401 decreased the B95kDa band, which corresponds to MMP9, *via* a zymography assay. The reduced concentration of MMP9 in BM74240-induced cells further verified these findings. However, BM742401 did not alter the expression level of intracellular MMP9; thus, BM742401 may diminish MMP9 secretion to inhibit cancer metastasis. LncRNA olfactory receptor, family 3, subfamily A, member 4 (OR3A4), contributes to GC metastasis as it was found to be overexpressed in primary tumor tissue, metastatic tissue and in the peripheral blood. Upregulated OR3A4 induced MMP9, which is involved in the breakdown of the ECM[54]. LINC00052 play an oncogenous role in GC cells. It promotes GC cell migration and invasion through promoting the SMYD2 related β-catenin methylation to stabilize the its expression and activating Wnt/β-catenin pathway. When upregulating LINC00052 level in GC cells, MMP2, MMP9 and Cyclin D1 expression were upregulated while E-cadherin and P21 were downregulated. The downstream MMP2 and MMP9 are reported related to the breakdown of the ECM.

Degradation of the extracellular matrix is one way to modulate the tumor microenvironment, hypoxia is another key change in the tumor microenvironment that promotes tumor metastasis[55,56]. AK058003, a lncRNA that is induced by hypoxia, Is positively associated with γ-synuclein (SNCG) in GC cells. AK058003 and SNCG are both upregulated in hypoxic environment, and SNCG facilitates hypoxia-induced GC cell metastasis, which is regulated by AK058003. Thus, a novel hypoxia/lncRNA-AK058003/SNCG pathway that is related to metastasis was identified[57]. Wang *et al*[57] found that lncRNA AK058003 is increased in hypoxia-induced GC cells, where it facilitates GC cell migration and invasion *in vivo* and *in vitro*. AK058003 positively altered SNCG, a member of the synuclein family, by decreasing methylation of the SNCG gene CpG island. Elevated SNCG expression can also be induced by hypoxia, which in turn induces GC cell metastasis in primary tumor tissue. LncRNA BC005927 is induced by hypoxia and hypoxia inducible factor-1α(HIF-1α), which is a factor involved in hypoxia induced GC metastasis, through directly binding the HIF-1 response element to promote GC metastasis and invasion. Mechanism research found out that this hypoxia-induced auxo-action partially regulated by BPHB4[58].

**LNCRNAS INVOLVED IN** **ANGIOPOIESIS AND VASCULOGENIC MIMICRY**

Ample evidence has shown that the development of endothelial vessels (EVs) and vasculogenic mimicry (VM) supply nutrition to tumors and sustain tumor growth. Highly vascular tumors show an increased ability to develop metastases compared to tumors that lack adequate vascularization[59,60]. VM involves the formation of *de novo* channels by pluripotent embryonic-like and highly invasive tumor cells, mimicking tumor feeding[61]. VM has already been reported in melanoma, soft tissue sarcomas, GIST and hepatocellular carcinoma[62-65].

MALAT1, an oncogenic lncRNA, can increases tumorigenicity and metastasis in GC by facilitating VM and angiogenesis. MALAT1 induces the expression of β-catenin and E-cadherin and increases the p-ERK, p-FAK, and p-paxillin levels. MT1-MMP and MMPs 2 and 9, which are downstream of p-ERK, are consequently altered. MALAT1 functions as an active regulator of VM and EV through the E-cadherin/β-catenin complex and *via* the ERK/MMP and FAK/paxillin signaling pathways[17]. Another mechanism involving MALAT1 was discovered by which MLAT1 regulates the acetylation level of H3 histone in the EGFL7 promoter region to boost the EGFL7 expression level[66]. An intron of the EGFL7 gene, MiR-126, is pivotal in alterations of H3 histone acetylation but not methylation in the EGFL7 promoter in colorectal cancer and non-small cell lung cancer cells and cooperates with MALAT1 to alter angiogenesis[67,68]. Another lncRNA, C21orF96, which its upregulated in gastric tumor tissue, was found to be significantly higher in metastatic tissues compared to histologically normal lymph node tissues. Yang *et al*[69] determined that ectopic expression of C21orF96 promotes lymphangiogenesis of stomach neoplasms. With respect to VM, C21orF96 increases the number of tubulars, intersecting nods and the length of the tubes in human umbilical vein endothelial cells (HUVECs). Likewise, OR3A4, an oncogenic lncRNA, was found to facilitate the formation of tubules in HUVECs. Upregulated OR3A4 induces vascular endothelial growth factor C (VEGF-C), which is a known promotor of angiogenesis and vascular permeability[70]. Furthermore, the chicken embryo chorioallantoic membrane (CAM) assay demonstrated that OR3A4 promotes angiogenesis. OR3A4 may exert its effects by inhibiting PDLIM2, promoting MACC1 and GNB2L1, and directly targeting NTN4 to enhance metastasis and tumorigenesis in GC[54].

**LNCRNAS RELATED TO** **IMMUNE ESCAPE OF GC CELLS**

Immune escape, the third step of cancer immunoediting[71], reduces the immunogenicity of tumor cells, creating an immunosuppressive tumor microenvironment in which cancer cells can survive and grow[72]. Evading immune destruction has been deemed as a hallmark of cancer[73].

The classical lncRNA, HOTAIR, has been reported to promote GC progression and metastasis[74-77]. Song *et al*[18] determined that upregulated HOTAIR in GC cells positively correlates with human leukocyte antigen (HLA)-G levels both in tissue and peripheral blood samples. Furthermore, HOTAIR was also found to induce the expression of HLA-G at both the mRNA and protein secretion levels. HOTAIR directly interacts with miR-152 and decreases miR-152’s expression level, which reverses the miR-152-induced dysregulated activity of HLA-G 30UTR, while, Mut-HOTAIR fails to have the same effect. Thus, HOTAIR overexpression might play roles in tumor immune escape. Furthermore, polymerase chain reaction-restriction fragment length polymorphism (PCRRFLP) was used to detect three htSNPs of the HOTAIR gene (rs12826786 C > T, rs4759314 A > G, and rs10783618 C > T). In normal and GCA tumor tissues, rs12826786 presented higher HOTAIR expression levels than the CC genotype, and the sore T allele of rs12826786 increased the GCA risk and reduced the 5-year survival rates[78].

**LNCRNAS DYSREGULATED IN PERIPHERAL BLOOD AND IN GASTRIC JUICE**

Given that patients are usually asymptomatic and that relapsed GC patients have poor prognosis, many doctors recognize the importance of surveillance in detecting stomach neoplasms recurrence[79]. Studies shows have shown that’s hematogenous metastasis is the most frequent recurrence pattern during the first year following resection[80], and identification of a simple method to monitor patients, for example, using serum lncRNAs, is a top priority. Identification of a noninvasive approach with a high degree of sensibility and specificity is urgently needed to predict and monitor the prognosis of GC patients and the relapse of patients post-operation.

OR3A4 is upregulated in both metastasis tissue and serum[54], as is ZFAS1 and exosomal ZFAS1. The level of circulating ZFAS1 correlates with lymphatic metastasis and the TNM stage, when the area under the ROC curve is up to 0.792 (95%CI: 0.703-0.881, *P* < 0.001)[29]. AA174084 is not only ectopically expressed in GC tissue but is also expressed in plasma and in gastric juice. The expression of AA174084 in GC patients’ gastric juice is significantly higher than that in control groups. In addition, the amount of AA174084 in plasma decreases after patients undergo surgery and is positively correlated with invasion and lymphatic metastasis. Thus, AA174084 could serve as a potential biomarker to predict a patient’s prognosis[81]. The lncRNA RNA component of mitochondrial RNA processing endoribonuclease (RMRP) has been reported to be decreased in GC tissues, but increased in the plasma and gastric juice of GC patients. After subtotal gastrectomy, this aberrant expression dramatically declines. Importantly, the RMRP level in gastric juice or in plasma is not only sufficient for clinical detection but that method for RMRP detection are also more sensitive and specific than that for carcinoembryonic antigen (CEA) and carbohydrate antigen19-9 (CA199). These results could provide a new method for GC detection, and the postoperative decline of RMRP implies that this lncRNA has appropriate characteristics for prognostic prediction[82]. Five novel plasma lncRNAs (TINCR, CCAT2,AOC4P, BANCR and LINC00857) demonstrate excellent stability and show little to no change in hostile environments. The diagnostic significance of lncRNA-based Index I, established by logistic regression, is better than that of the CEA-based Index II. Since the lncRNA-based index declined dramatically two weeks post-operation, this index is highly effective in monitoring tumor recurrence. The lncRNA-based index significantly correlates with tumor size, depth of invasion, lymphatic metastasis and TNM stages[83].

Currently, the majority of GC research focuses on the expression level of lncRNAs in GC tissue, while merely of them have been found to be stable expressed in plasma. Though systematic evaluation of the lncRNAs mentioned above is lacking, those that are stable in circulation could be useful for predicting metastasis of primary tumors, but this assumption must be confirmed. Individual markers, such as a single lncRNA, may not be adequate for determining prognosis in GC, but interested readers could refer to the analysis by Zhang *et al*[83] and Shao *et al*[81]. The combination of several lncRNAs known to participate in GC progression may overcome these existing issues.

**LNCRNAS AND CLINICAL CORRELATION**

Recently, the seventh edition of tumor, node, metastasis (TNM) classification has been widely accepted[84]. Gu *et al*[85] identified patients diagnosed with GC in the first hospital of the China Medical University and the Liaoning Cancer Hospital from January 1980 to December 2009 and systematically reviewed the data. These authors found that according to the 7th edition of the TNM classification, classification of stage T4b and N0 as stage IIIA had statistical significance in regard to the survival outcome and in predicting prognoses in Chinese GC patients. Given that lymph node and distant metastasis were found to be key factors in the prognosis of GC patients, we identified the lncRNAs that correlated with lymph node, distant metastasis and the TNM stage, as shown in Table 1[14-17,23,25-30,32,33,35,36,40,43,44,53,57,58,69,74-78,80-132].

**CONCLUSION**

Utilizing a variety of techniques, including RT-PCR, computer-assisted microscopic image analysis, bioinformatics methods, ChIP assays, *etc.,* a myriad of lncRNAs have been found to participate in the proliferation, growth, invasion, metastasis, motility, and phenotype of GC cells, with dozens of them correlating with the invasion depth, size, lymph node metastasis, TNM stage, OS and DFS of GC tumors. In this review, we emphasize epithelial-mesenchymal transition, epigenetic regulation, and degradation of the extracellular matrix, angiopoiesis, vasculogenic mimicry and immune escape in examining the ectopic expression of lncRNAs. LncRNAs involved specific mechanism of regulation of GC progression could be helpful in GC treatment. Those lncRNAs who are considered as independent prognostic factor by survival analysis such as MALAT1[17], Sox2ot[106], OTUB1-isoform 2[110], PANDAR[111], *etc*., and those lncRNAs dramatically altered in postoperative GC patients such as FERI4[125], may be utilized as prognosis evaluation markers. Some lncRNAs increased in metastatic tissue compared to primary focus may be beneficial in predicting metastasis.

**REFERENCES**

1 **Siegel RL**, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin* 2016; **66**: 7-30 [PMID: 26742998 DOI: 10.3322/caac.21332]

2 **Chen W**, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. *CA Cancer J Clin* 2016; **66**: 115-132 [PMID: 26808342 DOI: 10.3322/caac.21338]

3 **Siegel RL**, Miller KD, Jemal A. Cancer Statistics, 2017. *CA Cancer J Clin* 2017; **67**: 7-30 [PMID: 28055103 DOI: 10.3322/caac.21387]

4 **Tanabe S**, Koizumi W, Mitomi H, Nakai H, Murakami S, Nagaba S, Kida M, Oida M, Saigenji K. Clinical outcome of endoscopic aspiration mucosectomy for early stage gastric cancer. *Gastrointest Endosc* 2002; **56**: 708-713 [PMID: 12397280 DOI: 10.1067/mge.2002.129085]

5 **Tanabe S**, Ishido K, Higuchi K, Sasaki T, Katada C, Azuma M, Naruke A, Kim M, Koizumi W. Long-term outcomes of endoscopic submucosal dissection for early gastric cancer: a retrospective comparison with conventional endoscopic resection in a single center. *Gastric Cancer* 2014; **17**: 130-136 [PMID: 23576197 DOI: 10.1007/s10120-013-0241-2]

6 **Diehl F**, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, Kinzler KW, Vogelstein B, Diaz LA Jr. Circulating mutant DNA to assess tumor dynamics. *Nat Med* 2008; **14**: 985-990 [PMID: 18670422 DOI: 10.1038/nm.1789]

7 **Hamakawa T**, Kukita Y, Kurokawa Y, Miyazaki Y, Takahashi T, Yamasaki M, Miyata H, Nakajima K, Taniguchi K, Takiguchi S, Mori M, Doki Y, Kato K. Monitoring gastric cancer progression with circulating tumour DNA. *Br J Cancer* 2015; **112**: 352-356 [PMID: 25490524 DOI: 10.1038/bjc.2014.609]

8 **Ferro A**, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, Negri E, La Vecchia C, Lunet N. Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype. *Eur J Cancer* 2014; **50**: 1330-1344 [PMID: 24650579 DOI: 10.1016/j.ejca.2014.01.029]

9 **Djebali S**, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, Tanzer A, Lagarde J, Lin W, Schlesinger F, Xue C, Marinov GK, Khatun J, Williams BA, Zaleski C, Rozowsky J, Röder M, Kokocinski F, Abdelhamid RF, Alioto T, Antoshechkin I, Baer MT, Bar NS, Batut P, Bell K, Bell I, Chakrabortty S, Chen X, Chrast J, Curado J, Derrien T, Drenkow J, Dumais E, Dumais J, Duttagupta R, Falconnet E, Fastuca M, Fejes-Toth K, Ferreira P, Foissac S, Fullwood MJ, Gao H, Gonzalez D, Gordon A, Gunawardena H, Howald C, Jha S, Johnson R, Kapranov P, King B, Kingswood C, Luo OJ, Park E, Persaud K, Preall JB, Ribeca P, Risk B, Robyr D, Sammeth M, Schaffer L, See LH, Shahab A, Skancke J, Suzuki AM, Takahashi H, Tilgner H, Trout D, Walters N, Wang H, Wrobel J, Yu Y, Ruan X, Hayashizaki Y, Harrow J, Gerstein M, Hubbard T, Reymond A, Antonarakis SE, Hannon G, Giddings MC, Ruan Y, Wold B, Carninci P, Guigó R, Gingeras TR. Landscape of transcription in human cells. *Nature* 2012; **489**: 101-108 [PMID: 22955620 DOI: 10.1038/nature11233]

10 **Criscione SW**, Zhang Y, Thompson W, Sedivy JM, Neretti N. Transcriptional landscape of repetitive elements in normal and cancer human cells. *BMC Genomics* 2014; **15**: 583 [PMID: 25012247 DOI: 10.1186/1471-2164-15-583]

11 **Novikova IV**, Hennelly SP, Tung CS, Sanbonmatsu KY. Rise of the RNA machines: exploring the structure of long non-coding RNAs. *J Mol Biol* 2013; **425**: 3731-3746 [PMID: 23467124 DOI: 10.1016/j.jmb.2013.02.030]

12 **Iyer MK**, Niknafs YS, Malik R, Singhal U, Sahu A, Hosono Y, Barrette TR, Prensner JR, Evans JR, Zhao S, Poliakov A, Cao X, Dhanasekaran SM, Wu YM, Robinson DR, Beer DG, Feng FY, Iyer HK, Chinnaiyan AM. The landscape of long noncoding RNAs in the human transcriptome. *Nat Genet* 2015; **47**: 199-208 [PMID: 25599403 DOI: 10.1038/ng.3192]

13 **Grammatikakis I**, Panda AC, Abdelmohsen K, Gorospe M. Long noncoding RNAs(lncRNAs) and the molecular hallmarks of aging. *Aging* (Albany NY) 2014; **6**: 992-1009 [PMID: 25543668 DOI: 10.18632/aging.100710]

14 **Chen D**, Liu L, Wang K, Yu H, Wang Y, Liu J, Guo Y, Zhang H. The role of MALAT-1 in the invasion and metastasis of gastric cancer. *Scand J Gastroenterol* 2017; **52**: 790-796 [PMID: 28276823 DOI: 10.1080/00365521.2017.1280531]

15 **Sun TT**, He J, Liang Q, Ren LL, Yan TT, Yu TC, Tang JY, Bao YJ, Hu Y, Lin Y, Sun D, Chen YX, Hong J, Chen H, Zou W, Fang JY. LncRNA GClnc1 Promotes Gastric Carcinogenesis and May Act as a Modular Scaffold of WDR5 and KAT2A Complexes to Specify the Histone Modification Pattern. *Cancer Discov* 2016; **6**: 784-801 [PMID: 27147598 DOI: 10.1158/2159-8290.cd-15-0921]

16 **Xu TP**, Huang MD, Xia R, Liu XX, Sun M, Yin L, Chen WM, Han L, Zhang EB, Kong R, De W, Shu YQ. Decreased expression of the long non-coding RNA FENDRR is associated with poor prognosis in gastric cancer and FENDRR regulates gastric cancer cell metastasis by affecting fibronectin1 expression. *J Hematol Oncol* 2014; **7**: 63 [PMID: 25167886 DOI: 10.1186/s13045-014-0063-7]

17 **Li Y**, Wu Z, Yuan J, Sun L, Lin L, Huang N, Bin J, Liao Y, Liao W. Long non-coding RNA MALAT1 promotes gastric cancer tumorigenicity and metastasis by regulating vasculogenic mimicry and angiogenesis. *Cancer Lett* 2017; **395**: 31-44 [PMID: 28268166 DOI: 10.1016/j.canlet.2017.02.035]

18 **Song B**, Guan Z, Liu F, Sun D, Wang K, Qu H. Long non-coding RNA HOTAIR promotes HLA-G expression via inhibiting miR-152 in gastric cancer cells. *Biochem Biophys Res Commun* 2015; **464**: 807-813 [PMID: 26187665 DOI: 10.1016/j.bbrc.2015.07.040]

19 **Bonnomet A**, Brysse A, Tachsidis A, Waltham M, Thompson EW, Polette M, Gilles C. Epithelial-to-mesenchymal transitions and circulating tumor cells. *J Mammary Gland Biol Neoplasia* 2010; **15**: 261-273 [PMID: 20449641 DOI: 10.1007/s10911-010-9174-0]

20 **Guarino M**. Epithelial-mesenchymal transition and tumour invasion. *Int J Biochem Cell Biol* 2007; **39**: 2153-2160 [PMID: 17825600 DOI: 10.1016/j.biocel.2007.07.011]

21 **Hurt JA**, Robertson AD, Burge CB. Global analyses of UPF1 binding and function reveal expanded scope of nonsense-mediated mRNA decay. *Genome Res* 2013; **23**: 1636-1650 [PMID: 23766421 DOI: 10.1101/gr.157354.113]

22 **Li L**, Geng Y, Feng R, Zhu Q, Miao B, Cao J, Fei S. The Human RNA Surveillance Factor UPF1 Modulates Gastric Cancer Progression by Targeting Long Non-Coding RNA MALAT1. *Cell Physiol Biochem* 2017; **42**: 2194-2206 [PMID: 28942451 DOI: 10.1159/000479994]

23 **Lee NK**, Lee JH, Ivan C, Ling H, Zhang X, Park CH, Calin GA, Lee SK. MALAT1 promoted invasiveness of gastric adenocarcinoma. *BMC Cancer* 2017; **17**: 46 [PMID: 28077118 DOI: 10.1186/s12885-016-2988-4]

24 **Liu YW**, Sun M, Xia R, Zhang EB, Liu XH, Zhang ZH, Xu TP, De W, Liu BR, Wang ZX. LincHOTAIR epigenetically silences miR34a by binding to PRC2 to promote the epithelial-to-mesenchymal transition in human gastric cancer. *Cell Death Dis* 2015; **6**: e1802 [PMID: 26136075 DOI: 10.1038/cddis.2015.150]

25 **Cai H**, Chen J, He B, Li Q, Li Y, Gao Y. A FOXM1 related long non-coding RNA contributes to gastric cancer cell migration. *Mol Cell Biochem* 2015; **406**: 31-41 [PMID: 25907137 DOI: 10.1007/s11010-015-2421-3]

26 **Saito T**, Kurashige J, Nambara S, Komatsu H, Hirata H, Ueda M, Sakimura S, Uchi R, Takano Y, Shinden Y, Iguchi T, Eguchi H, Ehata S, Murakami K, Sugimachi K, Mimori K. A Long Non-coding RNA Activated by Transforming Growth Factor-β is an Independent Prognostic Marker of Gastric Cancer. *Ann Surg Oncol* 2015; **22 Suppl 3**: S915-S922 [PMID: 25986864 DOI: 10.1245/s10434-015-4554-8]

27 **Chen DL**, Ju HQ, Lu YX, Chen LZ, Zeng ZL, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Xu DZ, Zhou ZW, Pelicano H, Huang P, Xie D, Wang FH, Li YH, Xu RH. Long non-coding RNA XIST regulates gastric cancer progression by acting as a molecular sponge of miR-101 to modulate EZH2 expression. *J Exp Clin Cancer Res* 2016; **35**: 142 [PMID: 27620004 DOI: 10.1186/s13046-016-0420-1]

28 **Yan K**, Tian J, Shi W, Xia H, Zhu Y. LncRNA SNHG6 is Associated with Poor Prognosis of Gastric Cancer and Promotes Cell Proliferation and EMT through Epigenetically Silencing p27 and Sponging miR-101-3p. *Cell Physiol Biochem* 2017; **42**: 999-1012 [PMID: 28683446 DOI: 10.1159/000478682]

29 **Pan L**, Liang W, Fu M, Huang ZH, Li X, Zhang W, Zhang P, Qian H, Jiang PC, Xu WR, Zhang X. Exosomes-mediated transfer of long noncoding RNA ZFAS1 promotes gastric cancer progression. *J Cancer Res Clin Oncol* 2017; **143**: 991-1004 [PMID: 28285404 DOI: 10.1007/s00432-017-2361-2]

30 **Zuo ZK**, Gong Y, Chen XH, Ye F, Yin ZM, Gong QN, Huang JS. TGFβ1-Induced LncRNA UCA1 Upregulation Promotes Gastric Cancer Invasion and Migration. *DNA Cell Biol* 2017; **36**: 159-167 [PMID: 28075173 DOI: 10.1089/dna.2016.3553]

31 **Gao J**, Cao R, Mu H. Long non-coding RNA UCA1 may be a novel diagnostic and predictive biomarker in plasma for early gastric cancer. *Int J Clin Exp Pathol* 2015; **8**: 12936-12942 [PMID: 26722487]

32 **Fu M**, Huang Z, Zang X, Pan L, Liang W, Chen J, Qian H, Xu W, Jiang P, Zhang X. Long noncoding RNA LINC00978 promotes cancer growth and acts as a diagnostic biomarker in gastric cancer. *Cell Prolif* 2018; **51** [PMID: 29271006 DOI: 10.1111/cpr.12425]

33 **Sun D**, Li X, He Y, Li W, Wang Y, Wang H, Jiang S, Xin Y. YAP1 enhances cell proliferation, migration, and invasion of gastric cancer in vitro and in vivo. *Oncotarget* 2016; **7**: 81062-81076 [PMID: 27835600 DOI: 10.18632/oncotarget.13188]

34 **Zhao J**, Liu Y, Zhang W, Zhou Z, Wu J, Cui P, Zhang Y, Huang G. Long non-coding RNA Linc00152 is involved in cell cycle arrest, apoptosis, epithelial to mesenchymal transition, cell migration and invasion in gastric cancer. *Cell Cycle* 2015; **14**: 3112-3123 [PMID: 26237576 DOI: 10.1080/15384101.2015.1078034]

35 **Zhao Y**, Guo Q, Chen J, Hu J, Wang S, Sun Y. Role of long non-coding RNA HULC in cell proliferation, apoptosis and tumor metastasis of gastric cancer: a clinical and in vitro investigation. *Oncol Rep* 2014; **31**: 358-364 [PMID: 24247585 DOI: 10.3892/or.2013.2850]

36 **Fan Y**, Wang YF, Su HF, Fang N, Zou C, Li WF, Fei ZH. Decreased expression of the long noncoding RNA LINC00261 indicate poor prognosis in gastric cancer and suppress gastric cancer metastasis by affecting the epithelial-mesenchymal transition. *J Hematol Oncol* 2016; **9**: 57 [PMID: 27439973 DOI: 10.1186/s13045-016-0288-8]

37 **Yu Y**, Li L, Zheng Z, Chen S, Chen E, Hu Y. Long non-coding RNA linc00261 suppresses gastric cancer progression via promoting Slug degradation. *J Cell Mol Med* 2017; **21**: 955-967 [PMID: 27878953 DOI: 10.1111/jcmm.13035]

38 **Wu ZQ**, Li XY, Hu CY, Ford M, Kleer CG, Weiss SJ. Canonical Wnt signaling regulates Slug activity and links epithelial-mesenchymal transition with epigenetic Breast Cancer 1, Early Onset (BRCA1) repression. *Proc Natl Acad Sci U S A* 2012; **109**: 16654-16659 [PMID: 23011797 DOI: 10.1073/pnas.1205822109]

39 **Raja**, Vidhya G. GSK3B regulates epithelial-mesenchymal transition and cancer stem cell properties and is a novel drug target for triple-negative breast cancer. 2017

40 **Zeng S**, Xie X, Xiao YF, Tang B, Hu CJ, Wang SM, Wu YY, Dong H, Li BS, Yang SM. Long noncoding RNA LINC00675 enhances phosphorylation of vimentin on Ser83 to suppress gastric cancer progression. *Cancer letters* 2017; **412**: 179

41 **Zhang X**, Liu W, Yang H, Tan L, Ao L, Liu J, Cao J, Cui Z. Inhibition of PPARα attenuates vimentin phosphorylation on Ser-83 and collapse of vimentin filaments during exposure of rat Sertoli cells in vitro to DBP. *Reprod Toxicol* 2014; **50**: 11-18 [PMID: 25291543 DOI: 10.1016/j.reprotox.2014.09.015]

42 **Dave JM**, Bayless KJ. Vimentin as an integral regulator of cell adhesion and endothelial sprouting. *Microcirculation* 2014; **21**: 333–344

43 **Xie M**, Nie FQ, Sun M, Xia R, Liu YW, Zhou P, De W, Liu XH. Decreased long noncoding RNA SPRY4-IT1 contributing to gastric cancer cell metastasis partly via affecting epithelial-mesenchymal transition. *J Transl Med* 2015; **13**: 250 [PMID: 26238992 DOI: 10.1186/s12967-015-0595-9]

44 **Han Y**, Ye J, Wu D, Wu P, Chen Z, Chen J, Gao S, Huang J. LEIGC long non-coding RNA acts as a tumor suppressor in gastric carcinoma by inhibiting the epithelial-to-mesenchymal transition. *BMC Cancer* 2014; **14**: 932 [PMID: 25496320 DOI: 10.1186/1471-2407-14-932]

45 **Beckedorff FC**, Amaral MS, Deocesanopereira C, Verjovskialmeida S. Long non-coding RNAs and their implications in cancer epigenetics. *Bioscience Reports* 2013; **33**: 667-675

46 Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Human Molecular Genetics 2007; 16 Spec No 1(1): R50

47 **Guo W**, Dong Z, Shi Y, Liu S, Liang J, Guo Y, Guo X, Shen S, Wang G. Methylation-mediated downregulation of long noncoding RNA LOC100130476 in gastric cardia adenocarcinoma. *Clin Exp Metastasis* 2016; **33**: 497-508 [PMID: 27189370 DOI: 10.1007/s10585-016-9794-x]

48 **Sun M**, Liu XH, Lu KH, Nie FQ, Xia R, Kong R, Yang JS, Xu TP, Liu YW, Zou YF, Lu BB, Yin R, Zhang EB, Xu L, De W, Wang ZX. EZH2-mediated epigenetic suppression of long noncoding RNA SPRY4-IT1 promotes NSCLC cell proliferation and metastasis by affecting the epithelial-mesenchymal transition. *Cell Death Dis* 2014; **5**: e1298 [PMID: 24967960 DOI: 10.1038/cddis.2014.256]

49 **Buchheit CL**, Weigel KJ, Schafer ZT. Cancer cell survival during detachment from the ECM: multiple barriers to tumour progression. *Nature* *Reviews Cancer* 2014; **14**: 632

50 **Jodele S**, Blavier L, Yoon JM, Declerck YA. Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression. *Cancer Metasta Revie* 2006; **25**: 35

51 **Hadler-Olsen E**, Winberg JO, Uhlin-Hansen L. Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets. *Bio J of Inter Soci Biol Medic* 2013; **34**: 2041-2051

52 **Wang ZQ**, He CY, Hu L, Shi HP, Li JF, Gu QL, Su LP, Liu BY, Li C, Zhu Z. Long noncoding RNA UCA1 promotes tumour metastasis by inducing GRK2 degradation in gastric cancer. *Cancer Lett* 2017; **408**: 10-21 [PMID: 28843497 DOI: 10.1016/j.canlet.2017.08.013]

53 **Park SM**, Park SJ, Kim HJ, Kwon OH, Kang TW, Sohn HA, Kim SK, Moo Noh S, Song KS, Jang SJ, Sung Kim Y, Kim SY. A known expressed sequence tag, BM742401, is a potent lincRNA inhibiting cancer metastasis. *Exp Mol Med* 2013; **45**: e31 [PMID: 23846333 DOI: 10.1038/emm.2013.59]

54 **Guo X**, Yang Z, Zhi Q, Wang D, Guo L, Li G, Miao R, Shi Y, Kuang Y. Long noncoding RNA OR3A4 promotes metastasis and tumorigenicity in gastric cancer. *Oncotarget* 2016; **7**: 30276-30294 [PMID: 26863570 DOI: 10.18632/oncotarget.7217]

55 **Majmundar AJ**, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. *Molecular cell* 2010; **40**: 294

56 **Majmundar AJ**, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. *Mol Cell* 2010; **40**: 294-309 [PMID: 20965423 DOI: 10.1016/j.molcel.2010.09.022]

57 **Wang Y**, Liu X, Zhang H, Sun L, Zhou Y, Jin H, Zhang H, Zhang H, Liu J, Guo H, Nie Y, Wu K, Fan D, Zhang H, Liu L. Hypoxia-inducible lncRNA-AK058003 promotes gastric cancer metastasis by targeting γ-synuclein. *Neoplasia* 2014; **16**: 1094-1106 [PMID: 25499222 DOI: 10.1016/j.neo.2014.10.008]

58 **Liu X**, Wang Y, Sun L, Min J, Liu J, Chen D, Zhang H, Zhang H, Zhang H, Zhou Y, Liu L. Long noncoding RNA BC005927 upregulates EPHB4 and promotes gastric cancer metastasis under hypoxia. *Cancer Sci* 2018; **109**: 988-1000 [PMID: 29383777 DOI: 10.1111/cas.13519]

59 **Koliopanos A**, Avgerinos C, Paraskeva C, Touloumis Z, Kelgiorgi D, Dervenis C. *Molecu aspe carcinogene pancre cancer* 2008; **7**: 345-356

60 **Coomber BL**, Yu JL, Fathers KE, Plumb C, Rak JW. Angiogenesis and the role of epigenetics in metastasis. *Clini experimen metasta* 2003; **20**: 215

61 **Chen X**, Maniotis AJ, Majumdar D, Pe'Er J, Folberg R. Uveal melanoma cell staining for CD34 and assessment of tumor vascularity. *Investigat Ophthalmol Visu Scie* 2002; **43**: 2533-2539

62 **Sun B**, Zhang S, Zhang D, Du J, Guo H, Zhao X, Zhang W, Hao X. Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma. *Oncol repor* 2006; **16**: 693-698

63 **Maniotis AJ**, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'Er J, Trent JM, Meltzer PS, Hendrix MJ. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. *Americ J Pathol* 1999; **155**: 739

64 **Sun B**, Zhang S, Zhao X, Zhang W, Hao X, Sun, B, Zhang, S, Zhao, X, Zhang W, Hao X. Vasculogenic mimicry is associated with poor survival in patients with mesothelial sarcomas and alveolar rhabdomyosarcomas. *Int J Oncol* 2005; **25**: 1609-1614

65 **Sun B**, Qie S, Zhang S, Sun T, Zhao X, Gao S, Ni C, Wang X, Liu Y, Zhang L. Role and mechanism of vasculogenic mimicry in gastrointestinal stromal tumors. *Hum Pathol* 2008; **39**: 444

66 **Deng QJ**, Xie LQ, Li H. Overexpressed MALAT1 promotes invasion and metastasis of gastric cancer cells via increasing EGFL7 expression. *Life Sci* 2016; **157**: 38-44 [PMID: 27259812 DOI: 10.1016/j.lfs.2016.05.041]

67 **Hansen TF**, Christensen RD, Andersen RF, Sørensen FB, Johnsson A, Jakobsen A. MicroRNA-126 and epidermal growth factor-like domain 7|[ndash]|an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial. *Bri J Cancer* 2013; **109**: 1243

68 **Sun Y**, Bai Y, Zhang F, Wang Y, Guo Y, Guo L. miR-126 inhibits non-small cell lung cancer cells proliferation by targeting EGFL7. *Biophyl Resea Communica* 2010; **391**: 1483-1489

69 **Yang Z**, Zhi Q, Wang D, Zhang L, Preston B, Brandon C, Kuang Y, Miao R, Shi Y, Guo X. Long Noncoding RNA C21orF96 Promotes the Migration, Invasion and Lymph Node Metastasis in Gastric Cancer. *Anticancer Agents Med Chem* 2016; **16**: 1101-1108 [PMID: 26567621]

70 **Kamei S**, Kono K, Amemiya H, Takahashi A, Sugai H, Ichihara F, Fujii H, Matsumoto Y. Evaluation of VEGF and VEGF-C expression in gastric cancer cells producing alpha-fetoprotein. *J Gastroenterol* 2003; **38**: 540-547 [PMID: 12825129 DOI: 10.1007/s00535-002-1099-y]

71 **Koebel CM**, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD. Adaptive immunity maintains occult cancer in an equilibrium state. *Nature* 2007; **450**: 903-907 [PMID: 18026089 DOI: 10.1038/nature06309]

72 **Khong HT**, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. *Nat Immunol* 2002; **3**: 999-1005 [PMID: 12407407 DOI: 10.1038/ni1102-999]

73 **Hanahan D**, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011; **144**: 646-674 [PMID: 21376230 DOI: 10.1016/j.cell.2011.02.013]

74 **Li CY**, Liang GY, Yao WZ, Sui J, Shen X, Zhang YQ, Peng H, Hong WW, Ye YC, Zhang ZY, Zhang WH, Yin LH, Pu YP. Integrated analysis of long non-coding RNA competing interactions reveals the potential role in progression of human gastric cancer. *Int J Oncol* 2016; **48**: 1965-1976 [PMID: 26935047 DOI: 10.3892/ijo.2016.3407]

75 **Zhang ZZ**, Shen ZY, Shen YY, Zhao EH, Wang M, Wang CJ, Cao H, Xu J. HOTAIR Long Noncoding RNA Promotes Gastric Cancer Metastasis through Suppression of Poly r(C)-Binding Protein (PCBP) 1. *Mol Cancer Ther* 2015; **14**: 1162-1170 [PMID: 25612617 DOI: 10.1158/1535-7163.mct-14-0695]

76 **Lee NK**, Lee JH, Park CH, Yu D, Lee YC, Cheong JH, Noh SH, Lee SK. Long non-coding RNA HOTAIR promotes carcinogenesis and invasion of gastric adenocarcinoma. *Biochem Biophys Res Commun* 2014; **451**: 171-178 [PMID: 25063030 DOI: 10.1016/j.bbrc.2014.07.067]

77 **Okugawa Y**, Toiyama Y, Hur K, Toden S, Saigusa S, Tanaka K, Inoue Y, Mohri Y, Kusunoki M, Boland CR, Goel A. Metastasis-associated long non-coding RNA drives gastric cancer development and promotes peritoneal metastasis. *Carcinogenesis* 2014; **35**: 2731-2739 [PMID: 25280565 DOI: 10.1093/carcin/bgu200]

78 **Guo W**, Dong Z, Bai Y, Guo Y, Shen S, Kuang G, Xu J. Associations between polymorphisms of HOTAIR and risk of gastric cardia adenocarcinoma in a population of north China. *Tumour Biol* 2015; **36**: 2845-2854 [PMID: 25476857 DOI: 10.1007/s13277-014-2912-y]

79 **Hondo FY**, Kishi H, Safatle-Ribeiro AV, Pessorrusso FCS, Ribeiro U, Maluf-Filho F. CHARACTERIZATION OF THE MUCIN PHENOTYPE CAN PREDICT GASTRIC CANCER RECURRENCE AFTER ENDOSCOPIC MUCOSAL RESECTION. *Arq Gastroenterol* 2017; **54**: 308-314 [PMID: 28954038 DOI: 10.1590/s0004-2803.201700000-38]

80 **Eom BW**, Yoon H, Ryu KW, Lee JH, Cho SJ, Lee JY, Kim CG, Choi IJ, Lee JS, Kook MC, Park SR, Nam BH, Kim YW. Predictors of timing and patterns of recurrence after curative resection for gastric cancer. *Dig Surg* 2010; **27**: 481-486 [PMID: 21063125 DOI: 10.1159/000320691]

81 **Shao Y**, Ye M, Jiang X, Sun W, Ding X, Liu Z, Ye G, Zhang X, Xiao B, Guo J. Gastric juice long noncoding RNA used as a tumor marker for screening gastric cancer. *Cancer* 2014; **120**: 3320-3328 [PMID: 24986041 DOI: 10.1002/cncr.28882]

82 **Shao Y**, Ye M, Li Q, Sun W, Ye G, Zhang X, Yang Y, Xiao B, Guo J. LncRNA-RMRP promotes carcinogenesis by acting as a miR-206 sponge and is used as a novel biomarker for gastric cancer. *Oncotarget* 2016; **7**: 37812-37824 [PMID: 27192121 DOI: 10.18632/oncotarget.9336]

83 **Zhang K**, Shi H, Xi H, Wu X, Cui J, Gao Y, Liang W, Hu C, Liu Y, Li J, Wang N, Wei B, Chen L. Genome-Wide lncRNA Microarray Profiling Identifies Novel Circulating lncRNAs for Detection of Gastric Cancer. *Theranostics* 2017; **7**: 213-227 [PMID: 28042329 DOI: 10.7150/thno.16044]

84 **Montes HZ**.TNM Classification of Malignant Tumors, 7th edition. *Inter J Radia Oncol Biol Phys* 2010; **78**: 1278

85 **Gu H**, Li D, Zhu H, Zhang H, Yu Y, Qin D, Yi M, Li X, Lu P. The prognostic efficacy and improvements of the 7th edition Union for International Cancer Control tumor-node-metastasis classifications for Chinese patients with gastric cancer: Results based on a retrospective three-decade population study. *Tumour Biol* 2017; **39**: 1010428317694548 [PMID: 28351302 DOI: 10.1177/1010428317694548]

86 **Zhang Y**, Chen Z, Li MJ, Guo HY, Jing NC. Long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 regulates the expression of Gli2 by miR-202 to strengthen gastric cancer progression. *Biomed Pharmacother* 2017; **85**: 264-271 [PMID: 27887846 DOI: 10.1016/j.biopha.2016.11.014]

87 **Xia H**, Chen Q, Chen Y, Ge X, Leng W, Tang Q, Ren M, Chen L, Yuan D, Zhang Y, Liu M, Gong Q, Bi F. The lncRNA MALAT1 is a novel biomarker for gastric cancer metastasis. *Oncotarget* 2016; **7**: 56209-56218 [PMID: 27486823 DOI: 10.18632/oncotarget.10941]

88 **Liu XH**, Sun M, Nie FQ, Ge YB, Zhang EB, Yin DD, Kong R, Xia R, Lu KH, Li JH, De W, Wang KM, Wang ZX. Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer. *Mol Cancer* 2014; **13**: 92 [PMID: 24775712 DOI: 10.1186/1476-4598-13-92]

89 **Endo H**, Shiroki T, Nakagawa T, Yokoyama M, Tamai K, Yamanami H, Fujiya T, Sato I, Yamaguchi K, Tanaka N, Iijima K, Shimosegawa T, Sugamura K, Satoh K. Enhanced expression of long non-coding RNA HOTAIR is associated with the development of gastric cancer. *PLoS One* 2013; **8**: e77070 [PMID: 24130837 DOI: 10.1371/journal.pone.0077070]

90 **Hajjari M**, Behmanesh M, Sadeghizadeh M, Zeinoddini M. Up-regulation of HOTAIR long non-coding RNA in human gastric adenocarcinoma tissues. *Med Oncol* 2013; **30**: 670 [PMID: 23888369 DOI: 10.1007/s12032-013-0670-0]

91 **Chen WM**, Huang MD, Sun DP, Kong R, Xu TP, Xia R, Zhang EB, Shu YQ. Long intergenic non-coding RNA 00152 promotes tumor cell cycle progression by binding to EZH2 and repressing p15 and p21 in gastric cancer. *Oncotarget* 2016; **7**: 9773-9787 [PMID: 26799422 DOI: 10.18632/oncotarget.6949]

92 **Peng W**, Wu G, Fan H, Wu J, Feng J. Long noncoding RNA SPRY4-IT1 predicts poor patient prognosis and promotes tumorigenesis in gastric cancer. *Tumour Biol* 2015; **36**: 6751-6758 [PMID: 25835973 DOI: 10.1007/s13277-015-3376-4]

93 **Chen SX**, Yin JF, Lin BC, Su HF, Zheng Z, Xie CY, Fei ZH. Upregulated expression of long noncoding RNA SNHG15 promotes cell proliferation and invasion through regulates MMP2/MMP9 in patients with GC. *Tumour Biol* 2016; **37**: 6801-6812 [PMID: 26662309 DOI: 10.1007/s13277-015-4404-0]

94 **Hu Y**, Ma Z, He Y, Liu W, Su Y, Tang Z. LncRNA-SNHG1 contributes to gastric cancer cell proliferation by regulating DNMT1. *Biochem Biophys Res Commun* 2017; **491**: 926-931 [PMID: 28754593 DOI: 10.1016/j.bbrc.2017.07.137]

95 **Zhao L**, Guo H, Zhou B, Feng J, Li Y, Han T, Liu L, Li L, Zhang S, Liu Y, Shi J, Zheng D. Long non-coding RNA SNHG5 suppresses gastric cancer progression by trapping MTA2 in the cytosol. *Oncogene* 2016; **35**: 5770-5780 [PMID: 27065326 DOI: 10.1038/onc.2016.110]

96 **Li H**, Zhu H, Zhou Y, Wang H, Niu Z, Shen Y, Lv L. Long non-coding RNA MSTO2P promotes the proliferation and colony formation in gastric cancer by indirectly regulating miR-335 expression. *Tumour Biol* 2017; **39**: 1010428317705506 [PMID: 28618927 DOI: 10.1177/1010428317705506]

97 **Zhang LL**, Zhang LF, Guo XH, Zhang DZ, Yang F, Fan YY. Downregulation of miR-335-5p by Long Noncoding RNA ZEB1-AS1 in Gastric Cancer Promotes Tumor Proliferation and Invasion. *DNA Cell Biol* 2018; **37**: 46-52 [PMID: 29215918 DOI: 10.1089/dna.2017.3926]

98 **Bi M**, Yu H, Huang B, Tang C. Long non-coding RNA PCAT-1 over-expression promotes proliferation and metastasis in gastric cancer cells through regulating CDKN1A. *Gene* 2017; **626**: 337-343 [PMID: 28571676 DOI: 10.1016/j.gene.2017.05.049]

99 **Zheng L**, Chen J, Zhou Z, He Z. Knockdown of long non-coding RNA HOXD-AS1 inhibits gastric cancer cell growth via inactivating the JAK2/STAT3 pathway. *Tumour Biol* 2017; **39**: 1010428317705335 [PMID: 28475004 DOI: 10.1177/1010428317705335]

100 **Liu JN**, Shangguan YM. Long non-coding RNA CARLo-5 upregulation associates with poor prognosis in patients suffering gastric cancer. *Eur Rev Med Pharmacol Sci* 2017; **21**: 530-534 [PMID: 28239816]

101 **Huang M**, Hou J, Wang Y, Xie M, Wei C, Nie F, Wang Z, Sun M. Long Noncoding RNA LINC00673 Is Activated by SP1 and Exerts Oncogenic Properties by Interacting with LSD1 and EZH2 in Gastric Cancer. *Mol Ther* 2017; **25**: 1014-1026 [PMID: 28214253 DOI: 10.1016/j.ymthe.2017.01.017]

102 **Fei ZH**, Yu XJ, Zhou M, Su HF, Zheng Z, Xie CY. Upregulated expression of long non-coding RNA LINC00982 regulates cell proliferation and its clinical relevance in patients with gastric cancer. *Tumour Biol* 2016; **37**: 1983-1993 [PMID: 26334618 DOI: 10.1007/s13277-015-3979-9]

103 **Shao Y**, Chen H, Jiang X, Chen S, Li P, Ye M, Li Q, Sun W, Guo J. Low expression of lncRNA-HMlincRNA717 in human gastric cancer and its clinical significances. *Tumour Biol* 2014; **35**: 9591-9595 [PMID: 24961350 DOI: 10.1007/s13277-014-2243-z]

104 **Huang T**, Liu HW, Chen JQ, Wang SH, Hao LQ, Liu M, Wang B. The long noncoding RNA PVT1 functions as a competing endogenous RNA by sponging miR-186 in gastric cancer. *Biomed Pharmacother* 2017; **88**: 302-308 [PMID: 28122299 DOI: 10.1016/j.biopha.2017.01.049]

105 **Shen W**, Yuan Y, Zhao M, Li J, Xu J, Lou G, Zheng J, Bu S, Guo J, Xi Y. Novel long non-coding RNA GACAT3 promotes gastric cancer cell proliferation through the IL-6/STAT3 signaling pathway. *Tumour Biol* 2016; **37**: 14895-14902 [PMID: 27644247 DOI: 10.1007/s13277-016-5372-8]

106 **Zou JH**, Li CY, Bao J, Zheng GQ. High expression of long noncoding RNA Sox2ot is associated with the aggressive progression and poor outcome of gastric cancer. *Eur Rev Med Pharmacol Sci* 2016; **20**: 4482-4486 [PMID: 27874951]

107 **Chang S**, Liu J, Guo S, He S, Qiu G, Lu J, Wang J, Fan L, Zhao W, Che X. HOTTIP and HOXA13 are oncogenes associated with gastric cancer progression. *Oncol Rep* 2016; **35**: 3577-3585 [PMID: 27108607 DOI: 10.3892/or.2016.4743]

108 **Fu JW**, Kong Y, Sun X. Long noncoding RNA NEAT1 is an unfavorable prognostic factor and regulates migration and invasion in gastric cancer. *J Cancer Res Clin Oncol* 2016; **142**: 1571-1579 [PMID: 27095450 DOI: 10.1007/s00432-016-2152-1]

109 **Ma Y**, Liu L, Yan F, Wei W, Deng J, Sun J. Enhanced expression of long non-coding RNA NEAT1 is associated with the progression of gastric adenocarcinomas. *World J Surg Oncol* 2016; **14**: 41 [PMID: 26911892 DOI: 10.1186/s12957-016-0799-3]

110 **Wang YQ**, Zhang QY, Weng WW, Wu Y, Yang YS, Shen C, Chen XC, Wang L, Liu KJ, Xu MD, Sheng WQ. Upregulation of the Non-Coding RNA OTUB1-isoform 2 Contributes to Gastric Cancer Cell Proliferation and Invasion and Predicts Poor Gastric Cancer Prognosis. *Int J Biol Sci* 2016; **12**: 545-557 [PMID: 27019636 DOI: 10.7150/ijbs.13540]

111 **Ma P**, Xu T, Huang M, Shu Y. Increased expression of LncRNA PANDAR predicts a poor prognosis in gastric cancer. *Biomed Pharmacother* 2016; **78**: 172-176 [PMID: 26898439 DOI: 10.1016/j.biopha.2016.01.025]

112 **Lai Y**, Xu P, Li Q, Ren D, Wang J, Xu K, Gao W. Downregulation of long noncoding RNA ZMAT1 transcript variant 2 predicts a poor prognosis in patients with gastric cancer. *Int J Clin Exp Pathol* 2015; **8**: 5556-5562 [PMID: 26191264]

113 **Yang H**, Liu Z, Yuan C, Zhao Y, Wang L, Hu J, Xie D, Wang L, Chen D. Elevated JMJD1A is a novel predictor for prognosis and a potential therapeutic target for gastric cancer. *Int J Clin Exp Pathol* 2015; **8**: 11092-11099 [PMID: 26617828]

114 **Dang Y**, Lan F, Ouyang X, Wang K, Lin Y, Yu Y, Wang L, Wang Y, Huang Q. Expression and clinical significance of long non-coding RNA HNF1A-AS1 in human gastric cancer. *World J Surg Oncol* 2015; **13**: 302 [PMID: 26472090 DOI: 10.1186/s12957-015-0706-3]

115 **Li L**, Zhang L, Zhang Y, Zhou F. Increased expression of LncRNA BANCR is associated with clinical progression and poor prognosis in gastric cancer. *Biomed Pharmacother* 2015; **72**: 109-112 [PMID: 26054683 DOI: 10.1016/j.biopha.2015.04.007]

116 **Shan T**, Fan J, Zhao Q, Deng K, Xia J. Upregulation of long non-coding RNA DQ786243 promotes the progression of gastric cancer. *Mol Med Rep* 2017; **16**: 3761-3768 [PMID: 28731138 DOI: 10.3892/mmr.2017.7062]

117 **Song W**, Liu YY, Peng JJ, Liang HH, Chen HY, Chen JH, He WL, Xu JB, Cai SR, He YL. Identification of differentially expressed signatures of long non-coding RNAs associated with different metastatic potentials in gastric cancer. *J Gastroenterol* 2016; **51**: 119-129 [PMID: 26045391 DOI: 10.1007/s00535-015-1091-y]

118 **Wang CY**, Hua L, Yao KH, Chen JT, Zhang JJ, Hu JH. Long non-coding RNA CCAT2 is up-regulated in gastric cancer and associated with poor prognosis. *Int J Clin Exp Pathol* 2015; **8**: 779-785 [PMID: 25755774]

119 **Wu SW**, Hao YP, Qiu JH, Zhang DB, Yu CG, Li WH. High expression of long non-coding RNA CCAT2 indicates poor prognosis of gastric cancer and promotes cell proliferation and invasion. *Minerva Med* 2017; **108**: 317-323 [PMID: 28248065 DOI: 10.23736/s0026-4806.17.04703-6]

120 **Hu Y**, Pan J, Wang Y, Li L, Huang Y. Long noncoding RNA linc-UBC1 is negative prognostic factor and exhibits tumor pro-oncogenic activity in gastric cancer. *Int J Clin Exp Pathol* 2015; **8**: 594-600 [PMID: 25755750]

121 **Chen WM**, Huang MD, Kong R, Xu TP, Zhang EB, Xia R, Sun M, De W, Shu YQ. Antisense Long Noncoding RNA HIF1A-AS2 Is Upregulated in Gastric Cancer and Associated with Poor Prognosis. *Dig Dis Sci* 2015; **60**: 1655-1662 [PMID: 25686741 DOI: 10.1007/s10620-015-3524-0]

122 **Zhou B**, Jing XY, Wu JQ, Xi HF, Lu GJ. Down-regulation of long non-coding RNA LET is associated with poor prognosis in gastric cancer. *Int J Clin Exp Pathol* 2014; **7**: 8893-8898 [PMID: 25674261]

123 **Xu MD**, Qi P, Weng WW, Shen XH, Ni SJ, Dong L, Huang D, Tan C, Sheng WQ, Zhou XY, Du X. Long non-coding RNA LSINCT5 predicts negative prognosis and exhibits oncogenic activity in gastric cancer. *Medicine* (Baltimore) 2014; **93**: e303 [PMID: 25526476 DOI: 10.1097/md.0000000000000303]

124 **Xu C**, Shao Y, Xia T, Yang Y, Dai J, Luo L, Zhang X, Sun W, Song H, Xiao B, Guo J. lncRNA-AC130710 targeting by miR-129-5p is upregulated in gastric cancer and associates with poor prognosis. *Tumour Biol* 2014; **35**: 9701-9706 [PMID: 24969565 DOI: 10.1007/s13277-014-2274-5]

125 **Liu Z**, Shao Y, Tan L, Shi H, Chen S, Guo J. Clinical significance of the low expression of FER1L4 in gastric cancer patients. *Tumour Biol* 2014; **35**: 9613-9617 [PMID: 24961353 DOI: 10.1007/s13277-014-2259-4]

126 **Liu L**, Yan B, Yang Z, Zhang X, Gu Q, Yue X. ncRuPAR inhibits gastric cancer progression by down-regulating protease-activated receptor-1. *Tumour Biol* 2014; **35**: 7821-7829 [PMID: 24817013 DOI: 10.1007/s13277-014-2042-6]

127 **Li H**, Yu B, Li J, Su L, Yan M, Zhu Z, Liu B. Overexpression of lncRNA H19 enhances carcinogenesis and metastasis of gastric cancer. *Oncotarget* 2014; **5**: 2318-2329 [PMID: 24810858 DOI: 10.18632/oncotarget.1913]

128 **Zhang EB**, Han L, Yin DD, Kong R, De W, Chen J. c-Myc-induced, long, noncoding H19 affects cell proliferation and predicts a poor prognosis in patients with gastric cancer. *Med Oncol* 2014; **31**: 914 [PMID: 24671855 DOI: 10.1007/s12032-014-0914-7]

129 **Sun W**, Wu Y, Yu X, Liu Y, Song H, Xia T, Xiao B, Guo J. Decreased expression of long noncoding RNA AC096655.1-002 in gastric cancer and its clinical significance. *Tumour Biol* 2013; **34**: 2697-2701 [PMID: 23645148 DOI: 10.1007/s13277-013-0821-0]

130 **Mei D**, Song H, Wang K, Lou Y, Sun W, Liu Z, Ding X, Guo J. Up-regulation of SUMO1 pseudogene 3 (SUMO1P3) in gastric cancer and its clinical association. *Med Oncol* 2013; **30**: 709 [PMID: 23996296 DOI: 10.1007/s12032-013-0709-2]

131 **Lu Y**, Lu P, Zhu Z, Xu H, Zhu X. Loss of imprinting of insulin-like growth factor 2 is associated with increased risk of lymph node metastasis and gastric corpus cancer. *J Exp Clin Cancer Res* 2009; **28**: 125 [PMID: 19737423 DOI: 10.1186/1756-9966-28-125]

132 **Li X**, Zhou Y, Qian H. CCAT1 expressed in malignant and pre-malignant human gastric tissues. *Cell Mol Biol* (Noisy-le-grand) 2017; **63**: 89-93 [PMID: 28719351 DOI: 10.14715/cmb/2017.63.5.16]

**P-Reviewer:** Das U, Mavridis K **S-Editor:** Wang XJ

**L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** China

**Peer-review report classification**


Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

****

**Figure 1 Long non-coding RNAs affect epithelial-mesenchymal transition in gastric cancer cells.** A: HOTAIR recruits PRC2 to silence miR34a, and then activates the HGF/c-Met /Snail pathway to promote EMT; B: TGF-β induces lncATB, which inhibits miR200s and provokes ZEB1 to promote EMT; C:SNHG6 binds miR101-3P to activate ZEB1 and then promotes EMT; D: lncRNA ZFAS1 induces EMT by activating SNAIL, Slug, ZEB1 and Twist; E: Linc00978 induces Twist and TGFβ1，and TGFβ1 then activates SMAD2 and MMP9 to facilitate EMT; F: MALAT1 binds UPF1 to reduce its level and activate EMT; G: FRLnC1 induces EMT by activating Twist and TGFβ1; H: HUCA1 induces EMT *via* TGFβ1 activation; I: YAP1 through increasing vimentin and β-catenin, decreasing E-cadherin to promote EMT; J: lncRNA XIST, Linc00152 and HULC promote EMT; K: Linc00261 binds Slug resulting in reduced Slug levels and decreased EMT; L: LINC00675 and SPRY4-IT1 restrain EMT by reducing vimentin; M: LEIGC inhibits EMT. lncRNAs: Long non-coding RNAs; HOTAIR: HOX transcript antisense intergenic RNA; EMT: Epithelial-mesenchymal transition; YAP1: Yes-associated protein 1; MALAT1: Metastasis associated lung adenocarcinoma 1.

**Table 1 Mechanistic analysis of long non-coding RNAs involved in gastric cancer metastasis and clinical correlations**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| LncRNA ID | Dysregulation | Upstream regulators | Downstream targets | Metastasis processes | Clinical correlation | Univariate analysis (HR 95%CI) *P* < 0.05 | | Multivariate analysis(HR 95%CI) *P* < 0.05 | | Reference |
| OS | DFS | OS | DFS |
| MALAT1 | Up | JMJD1A | UPF1,  Snail,  N-cadherin,  ZEB1  VE-cadherin/β-catenin complex, ERK/MMP,  FAK/paxillin,EGFL7,miR122 | EMT,  Angiopoiesis, VM | Lymphatic metastasis,  distant metastasis,  TNM stage | 1.38 (1.03-1.85) | 1.40 (1.01-1.94) |  |  | [14,17,23,86,87] |
| HOTAIR | Up |  | PCR2, miR34a,  c-MET,  SNAIL1,  CDH1  miR-152, HLA-G | EMT,  immune escape | Lymphatic metastasis,  distant metastasis,  TNM stage |  |  |  |  | [74-76,78,88-90] |
| FRLnC | Up | FOXM1 | Twist, TGFβ-1 | EMT |  |  |  |  |  | [25] |
| UCA1 | Up |  | TGFβ-1  GRK2/ERK/MMP9 | EMT,  degradation of the ECM | Lymphatic metastasis,  TNM stage | 3.909 (1.592-9.599) |  | 2.917 (1.069-7.962) |  | [30,74] |
| ATB | Up | TGFβ-1 | miR200s, ZEB1 | EMT |  |  |  | 3.50 (1.73-7.44) |  | [26] |
| XIST | Up |  | miR101 | EMT | Lymphatic  metastasis,  distant metastasis,  TNM stage |  |  |  |  | [27] |
| SNHG-6 | Up |  | miR101-3P, ZEB1 | EMT | Lymphatic metastasis,  distant metastasis,  TNM stage |  |  |  |  | [28] |
| ZFAS1 | Up |  | ZEB1, SNAIL,  Slug, Twist | EMT | Lymphatic metastasis,  TNM stage |  |  |  |  | [29] |
| LINC00152 | Up |  |  | EMT | Lymphatic metastasis,  TNM stage | 2.162 (1.327-3.524) |  | 1.659 (1.008-2.731) |  | [91] |
| HULC | Up |  |  | EMT | Lymphatic metastasis,  distant metastasis,  TNM stage |  |  |  |  | [35] |
| Linc00978 | Up |  | TGFβ/SMAD,Twist1,  Slug | EMT | Lymphatic metastasis,  TNM stage |  |  |  |  | [32] |
| YAP1 | Up |  | vimentin,  β-catemin,  E-cadherin | EMT | Lymphatic metastasis,  distant metastasis,  TNM stage |  |  |  |  | [33] |
| Linc00261 | Down |  | Slug, GSK3β | EMT | Lymphatic, metastasis |  | 0.494 (0.300-0.812) |  | 0.551 (0.323-0.940) | [36] |
| Linc00675 | Down |  | Vimentin | EMT |  |  |  |  |  | [40] |
| SPRY4-IT1 | Down |  | Vimentin | EMT,  epigenetic regulation | Lymphatic  metastasis,  distant metastasis,  TNM stage | 1.247 (1473-1.996) | 2.223 (1.806-2.59) | 0.818 (0.314-1.567) | 1.741 (1.324-2477) | [43,92] |
| LEIGC | Down |  |  | EMT |  |  |  |  |  | [44] |
| GClnc1 | Up |  | WDR5/KAT2,  H3K4,H3K9,  SOD2 | Epigenetic regulation |  | 2.21 (1.46-3.33) |  | 1.93 (1.24-3.00) |  | [15] |
| LOC100130476 | Down | DNMT1 |  | Epigenetic regulation | Lymphatic metastasis,  distant metastasis,  TNM stage |  |  |  |  | [47] |
| AK058003 | Up |  | SNCG | Epigenetic regulation,  Hypoxia | Lymphatic metastasis,  TNM stage |  |  |  |  | [57] |
| BC005927 | Up | HIF-1α | BPHB4 | Hypoxia | Lymphatic metastasis,  TNM stage |  |  |  |  | [58] |
| SNHG15 | Up |  | MMP2,MMP9 | Degradation of the ECM | Lymphatic metastasis,  TNM stage |  |  |  |  | [93] |
| FENDRR | Down |  | MMP2,MMP9 | Degradation of the ECM | Lymphatic metastasis | 0.539 (0.337-0.862) | 0.563 (0.370-0.856) | 0.569 (0.321-0.960) | 0.555 (0.344-0.897) | [16] |
| BM742401 | Down |  | MMP9 | Degradation of the ECM |  |  |  |  |  | [53] |
| C21orF96 | Up |  |  | Lymphangiogenesis, VM | Lymphatic metastasis,  distant metastasis |  |  |  |  | [69] |
| LINC00052 | Up |  | Wnt/β-catenin pathway |  | TNM stage |  |  |  |  |  |
| AA174084 | Down |  |  |  |  |  |  |  |  | [81] |
| RMRP | Down |  |  |  | Lymphatic metastasis |  |  |  |  | [82] |
| SNHG1 | Up |  |  |  | Lymphatic metastasis,  TNM stage |  |  |  |  | [94] |
| SNHG5 | Down |  |  |  | TNM stage |  |  |  |  | [95] |
| MSTO2P | Up |  | miR-335 |  | Lymphatic metastasis,  distant metastasis |  |  |  |  | [96] |
| ZEB1-AS1 | Up |  | miR-335-5p |  | Lymphatic metastasis,  TNM stage |  |  |  |  | [97] |
| PTENP1 | Down |  | miR-106b, miR-93 |  | Lymphatic metastasis,  TNM stage |  |  |  |  |  |
| RP11-19P22.6-001 | Down |  | Nitric oxide synthase 2 (NOS2) |  | Lymphatic metastasis,  TNM stage |  |  |  |  |  |
| PCAT-1 | Up |  |  |  | distant metastasis |  |  |  |  | [98] |
| HOXD-ASI | Up |  |  |  | Lymphatic metastasis,  distant metastasis,  TNM stage |  |  |  |  | [99] |
| CARLo-5 | Up |  |  |  | Lymphatic metastasis,  distant metastasis |  |  |  |  | [100] |
| LINC00673 | Down |  |  |  | Lymphatic metastasis |  |  |  |  | [101] |
| LINC00982 | Down |  |  |  | Lymphatic metastasis,  TNM stage |  |  |  |  | [102] |
| HMlincRNA717 | Down |  |  |  | distant metastasis |  |  |  |  | [103] |
| PVT1 | Up |  |  |  | Lymphatic metastasis |  |  |  |  | [104] |
| GACAT3 | Up | IL-6/STAT3 |  |  | Distant metastasis,  TNM stage |  |  |  |  | [105] |
| Sox2ot | Down |  |  |  | Distant metastasis | 3.241 (1.239-6.428) |  | 3.844 (1.873-7.332) |  | [106] |
| HOTTIP | Up |  | HOXA13 |  | Lymphatic metastasis,  TNM stage |  |  |  |  | [107] |
| NEAT1 | Up |  |  |  | Lymphatic metastasis,  distant metastasis |  |  |  |  | [108,109] |
| OTUB1-isoform2 | Up |  | N-cadherin,  MMP2,MMP9,  E-cadherin |  | Lymphatic metastasis,  TNM stage | 1,538 (1.044-2.265) | 1.615 (1.111-2.348) |  | 1.498 (1.021-2.200) | [110] |
| PANDAR |  |  |  |  | Lymphatic metastasis,  TNM stage | 4.612 (1.59-13.825) | 3.113 (1.591-6.093) | 3.683 (1.125-12.058) | 2.359 (1.153-4.830) | [111] |
| ZMAT1 transcript variant 2 | Down |  |  |  | Lymphatic metastasis,  distant metastasis,  TNM stage |  |  |  |  | [112] |
| JMJD1A | Up |  | MALAT1,MAPK |  | Lymphatic metastasis,  TNM stage | 8.446 (4.480-15.923) |  | 3.988 (1.948-8.167) |  | [113] |
| OR3A4 | Up |  | PDLIM2,  MACC1,NTN4,  GNB2L1 | Degradation of the ECM, angiopoiesis, VM | Lymphatic metastasis  distant metastasis |  |  |  |  | [54] |
| HNF1A-AS1 | Down |  |  |  | Lymphatic metastasis |  |  |  |  | [114] |
| BANCR | Up |  |  |  | Lymphatic metastasis,  distant metastasis | 2.457 (1.715-3.521) |  | 1.511 (1.02-2.227) |  | [115] |
| DQ786243 | Up |  |  |  | Lymphatic metastasis,  TNM stage |  |  |  |  | [116] |
| XLOC\_010235 | Up |  |  |  | distant metastasis,  TNM stage |  |  |  |  | [117] |
| CCAT2 | Up |  |  |  | Lymphatic metastasis,  distant metastasis,  TNM stage | 2.631 (1.348-5.672) | 2.574 (1.201-5.476) | 2.405 (1.194-5.417) | 2.315 (1.097-5.283) | [118,119] |
| Linc-UBC1 | Up |  |  |  | Lymphatic metastasis,  TNM stage |  |  |  |  | [120] |
| HIF1A-AS2 | Up |  |  |  | Lymphatic metastasis,  TNM stage | 2.346 (1.379-3.991) |  | 1.724 (1.002-2.964) |  | [121] |
| LET | Down |  |  |  | Lymphatic metastasis,  distant metastasis,  TNM stage | 2.513 (1.414-5.847) |  | 2.275 (1.301-5.176) |  | [122] |
| LSINCT5 | Up |  |  |  | Lymphatic metastasis,  TNM stage |  | 2.501 (1.326-4.719) |  | 1.081 (1.286-3.564) | [123] |
| AC130710 | Up |  |  |  | distant metastasis,  TNM stage |  |  |  |  | [124] |
| FER1L4 | Down |  |  |  | Lymphatic metastasis,  distant metastasis,  TNM stage |  |  |  |  | [125] |
| RuPAR | Down |  |  |  | Lymphatic metastasis,  distant metastasis,  TNM stage |  |  |  |  | [126] |
| H19 | Up |  | miR-675 |  | Lymphatic metastasis,  TNM stage | 1.170 (1.050-1.304) |  | 1.137 (1.005-1.287) |  | [127,128] |
| AC096655.1-002 | Down |  |  |  | Lymphatic metastasis,  distant metastasis,  TNM stage |  |  |  |  | [129] |
| SUMO1P3 | Up |  |  |  | Lymphatic metastasis |  |  |  |  | [130] |
| IGF2 | Up |  |  |  | Lymphatic metastasis |  |  |  |  | [131] |
| CCAT1 | Up |  |  |  | Lymphatic metastasis,  TNM stage |  |  |  |  | [132] |

EMT: Epithelial-mesenchymal transition; VM: Vasculogenic mimicry; TNM: Tumor, node, metastasis; ECM: Extracellular matrix.